Thousands of UK patients with advanced kidney cancer who have been denied a combination regimen based on Ipsen’s Cabometyx and MSD’s Keytruda will now be able to access the treatment, following new guidance from NICE.
The advice provides a new first-line treatment option for an estimated 2,287 adults in England and Wales with advanced renal cell carcinoma (RCC), the most common form of kidney cancer.
